The European Parliament’s Committee on Women’s Rights and Gender Equality has adopted a draft report calling for stronger EU action to address gender inequalities in health, citing systemic bias across medical research, diagnosis and treatment.
The move, approved by the committee in Strasbourg, flags persistent disparities in how health systems and research frameworks recognise and respond to sex and gender differences. The report urges the European Union and member states to take concrete steps to ensure medical knowledge and care fully reflect women’s and other gendered populations’ needs.
Why it matters
Health policy shaped without adequate attention to sex and gender differences can leave large parts of the population at greater risk of misdiagnosis, delayed care, poorer outcomes and unequal access to treatments. Differences in symptom presentation, drug metabolism and disease progression between women and men have been documented across multiple conditions; the committee’s report frames these issues as systemic, rooted in how medical research is designed, how clinical trials are conducted, and how health-care providers are trained.
For EU policymakers, the report links gender-responsive health policy to broader European priorities: protecting citizens’ health, ensuring equal access to care, and improving the quality and cost-effectiveness of health systems. For businesses — particularly pharmaceutical companies and medical device manufacturers — it points to the need for research and product development that reflects diverse populations. For democracies and public trust in institutions, the findings underscore that perceived or real bias in health systems can undermine confidence in public health guidance and interventions.
Key elements of the committee’s draft report
The committee’s adopted draft identifies several areas where EU-level action is needed:
– Medical research: The report says research agendas, clinical trials and data collection still insufficiently integrate sex and gender analysis. This includes underrepresentation or inadequate reporting on female participants in trials and limited consideration of gendered variables that affect health outcomes.
– Diagnosis and treatment: It highlights examples of biased diagnostic criteria and treatment pathways that can lead to misdiagnosis or delayed treatment for women and gender-diverse people. The committee calls for care standards and clinical guidelines that explicitly account for sex and gender differences.
– Education and training: The draft recommends improving medical and public-health education so health professionals are equipped to recognise and manage sex- and gender-specific presentations of disease.
– Data and monitoring: Better sex-disaggregated and gender-sensitive data collection and monitoring are signalled as key to identifying disparities and measuring progress.
– EU coordination: The committee seeks stronger European-level coordination to harmonise approaches, share best practice, and ensure that EU research funding and regulatory frameworks promote gender-aware science and health care.
Background and context
The adoption of the draft by the Committee on Women’s Rights and Gender Equality adds momentum to a growing focus inside EU institutions on biological sex and gender as determinants of health. Over recent years, EU bodies and national authorities have increasingly acknowledged that one-size-fits-all models in medicine can disadvantage women and other gendered groups, and have begun to push for more inclusive research and policy design.
The committee’s report does not itself change law but is intended to inform the Parliament’s position and stimulate debate on next steps. Its adoption in committee is the stage that precedes potential adoption by the full Parliament, where MEPs will consider amendments and vote on whether to endorse the text.
Next steps
Following committee adoption, the draft report is likely to proceed to plenary for debate and a final vote. If adopted by the full Parliament, it could influence EU policy frameworks, funding priorities for research programmes, and recommendations to member states on clinical practice and education. The report may also feed into ongoing discussions on EU health policy coordination, research regulation and the design of future EU-funded health research calls.
The committee’s move places gender-aware health care squarely on the Parliament’s agenda, signalling an expectation that both EU institutions and national health systems step up efforts to identify and remedy systemic bias in medical research, diagnosis and treatment.
Source: Full Press Release
